Cargando…

Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus

Merkel cell carcinoma (MCC) is a rare neuroendocrine skin malignancy caused by human Merkel cell polyomavirus (MCV), leading to the most aggressive skin cancer in humans. MCV has been identified in approximately 43%–100% of MCC cases, contributing to the highly aggressive nature of primary cutaneous...

Descripción completa

Detalles Bibliográficos
Autores principales: Imon, Raihan Rahman, Samad, Abdus, Alam, Rahat, Alsaiari, Ahad Amer, Talukder, Md. Enamul Kabir, Almehmadi, Mazen, Ahammad, Foysal, Mohammad, Farhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333698/
https://www.ncbi.nlm.nih.gov/pubmed/37441076
http://dx.doi.org/10.3389/fimmu.2023.1160260
_version_ 1785070720500367360
author Imon, Raihan Rahman
Samad, Abdus
Alam, Rahat
Alsaiari, Ahad Amer
Talukder, Md. Enamul Kabir
Almehmadi, Mazen
Ahammad, Foysal
Mohammad, Farhan
author_facet Imon, Raihan Rahman
Samad, Abdus
Alam, Rahat
Alsaiari, Ahad Amer
Talukder, Md. Enamul Kabir
Almehmadi, Mazen
Ahammad, Foysal
Mohammad, Farhan
author_sort Imon, Raihan Rahman
collection PubMed
description Merkel cell carcinoma (MCC) is a rare neuroendocrine skin malignancy caused by human Merkel cell polyomavirus (MCV), leading to the most aggressive skin cancer in humans. MCV has been identified in approximately 43%–100% of MCC cases, contributing to the highly aggressive nature of primary cutaneous carcinoma and leading to a notable mortality rate. Currently, no existing vaccines or drug candidates have shown efficacy in addressing the ailment caused by this specific pathogen. Therefore, this study aimed to design a novel multiepitope vaccine candidate against the virus using integrated immunoinformatics and vaccinomics approaches. Initially, the highest antigenic, immunogenic, and non-allergenic epitopes of cytotoxic T lymphocytes, helper T lymphocytes, and linear B lymphocytes corresponding to the virus whole protein sequences were identified and retrieved for vaccine construction. Subsequently, the selected epitopes were linked with appropriate linkers and added an adjuvant in front of the construct to enhance the immunogenicity of the vaccine candidates. Additionally, molecular docking and dynamics simulations identified strong and stable binding interactions between vaccine candidates and human Toll-like receptor 4. Furthermore, computer-aided immune simulation found the real-life-like immune response of vaccine candidates upon administration to the human body. Finally, codon optimization was conducted on the vaccine candidates to facilitate the in silico cloning of the vaccine into the pET28+(a) cloning vector. In conclusion, the vaccine candidate developed in this study is anticipated to augment the immune response in humans and effectively combat the virus. Nevertheless, it is imperative to conduct in vitro and in vivo assays to evaluate the efficacy of these vaccine candidates thoroughly. These evaluations will provide critical insights into the vaccine’s effectiveness and potential for further development.
format Online
Article
Text
id pubmed-10333698
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103336982023-07-12 Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus Imon, Raihan Rahman Samad, Abdus Alam, Rahat Alsaiari, Ahad Amer Talukder, Md. Enamul Kabir Almehmadi, Mazen Ahammad, Foysal Mohammad, Farhan Front Immunol Immunology Merkel cell carcinoma (MCC) is a rare neuroendocrine skin malignancy caused by human Merkel cell polyomavirus (MCV), leading to the most aggressive skin cancer in humans. MCV has been identified in approximately 43%–100% of MCC cases, contributing to the highly aggressive nature of primary cutaneous carcinoma and leading to a notable mortality rate. Currently, no existing vaccines or drug candidates have shown efficacy in addressing the ailment caused by this specific pathogen. Therefore, this study aimed to design a novel multiepitope vaccine candidate against the virus using integrated immunoinformatics and vaccinomics approaches. Initially, the highest antigenic, immunogenic, and non-allergenic epitopes of cytotoxic T lymphocytes, helper T lymphocytes, and linear B lymphocytes corresponding to the virus whole protein sequences were identified and retrieved for vaccine construction. Subsequently, the selected epitopes were linked with appropriate linkers and added an adjuvant in front of the construct to enhance the immunogenicity of the vaccine candidates. Additionally, molecular docking and dynamics simulations identified strong and stable binding interactions between vaccine candidates and human Toll-like receptor 4. Furthermore, computer-aided immune simulation found the real-life-like immune response of vaccine candidates upon administration to the human body. Finally, codon optimization was conducted on the vaccine candidates to facilitate the in silico cloning of the vaccine into the pET28+(a) cloning vector. In conclusion, the vaccine candidate developed in this study is anticipated to augment the immune response in humans and effectively combat the virus. Nevertheless, it is imperative to conduct in vitro and in vivo assays to evaluate the efficacy of these vaccine candidates thoroughly. These evaluations will provide critical insights into the vaccine’s effectiveness and potential for further development. Frontiers Media S.A. 2023-06-27 /pmc/articles/PMC10333698/ /pubmed/37441076 http://dx.doi.org/10.3389/fimmu.2023.1160260 Text en Copyright © 2023 Imon, Samad, Alam, Alsaiari, Talukder, Almehmadi, Ahammad and Mohammad https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Imon, Raihan Rahman
Samad, Abdus
Alam, Rahat
Alsaiari, Ahad Amer
Talukder, Md. Enamul Kabir
Almehmadi, Mazen
Ahammad, Foysal
Mohammad, Farhan
Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus
title Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus
title_full Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus
title_fullStr Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus
title_full_unstemmed Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus
title_short Computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against Merkel cell polyomavirus
title_sort computational formulation of a multiepitope vaccine unveils an exceptional prophylactic candidate against merkel cell polyomavirus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333698/
https://www.ncbi.nlm.nih.gov/pubmed/37441076
http://dx.doi.org/10.3389/fimmu.2023.1160260
work_keys_str_mv AT imonraihanrahman computationalformulationofamultiepitopevaccineunveilsanexceptionalprophylacticcandidateagainstmerkelcellpolyomavirus
AT samadabdus computationalformulationofamultiepitopevaccineunveilsanexceptionalprophylacticcandidateagainstmerkelcellpolyomavirus
AT alamrahat computationalformulationofamultiepitopevaccineunveilsanexceptionalprophylacticcandidateagainstmerkelcellpolyomavirus
AT alsaiariahadamer computationalformulationofamultiepitopevaccineunveilsanexceptionalprophylacticcandidateagainstmerkelcellpolyomavirus
AT talukdermdenamulkabir computationalformulationofamultiepitopevaccineunveilsanexceptionalprophylacticcandidateagainstmerkelcellpolyomavirus
AT almehmadimazen computationalformulationofamultiepitopevaccineunveilsanexceptionalprophylacticcandidateagainstmerkelcellpolyomavirus
AT ahammadfoysal computationalformulationofamultiepitopevaccineunveilsanexceptionalprophylacticcandidateagainstmerkelcellpolyomavirus
AT mohammadfarhan computationalformulationofamultiepitopevaccineunveilsanexceptionalprophylacticcandidateagainstmerkelcellpolyomavirus